Study | All-cause mortality | Incidence of proven/probable IFI overall | Incidence of proven/probable IA | Incidence of proven IC | Incidence of OLAT use |
---|---|---|---|---|---|
Winston 2003 [29] | Â | Â | Â | Â | Â |
Fluconazole | 28/67 (42%) | 17/67 (25%) | 8/67 (12%) | 8/67 (12%) | Not reported |
Itraconazole | 32/71 (45%) | 6/71 (8%) | 3/71 (4%) | 2/71 (3%) | Not reported |
Marr 2004 [26] | Â | Â | Â | Â | Â |
Fluconazole | 44/148 (30%) | 25/148 (17%) | 20/148 (14%) | 5/148 (3%) | 25/148 (17%) |
Itraconazole | 55/151 (36%) | 19/151 (13%)a | 16/151 (11%) | 4/151 (3%) | 19/151 (13%) |
Ullmann 2007 [27] | Â | Â | Â | Â | Â |
Fluconazole | 59/299 (20%) | 27/299 (9%) | 21/299 (7%) | 4/299 (1%) | 29/288 (10%) |
Posaconazole | 58/301 (19%) | 16/301 (5%) | 7/301 (2%) | 4/301 (1%) | 31/291 (11%) |
Wingard 2010 [28] | Â | Â | Â | Â | Â |
Fluconazole | 59/295 (20%) | 24/295 (8%) | 17/295 (6%) | 5/295 (2%) | 89/295 (30%) |
Voriconazole | 57/305 (19%) | 14/305 (5%) | 9/305 (3%) | 3/305 (1%) | 73/305 (24%) |
Marks 2011 [10] | Â | Â | Â | Â | Â |
Itraconazole | 44/241 (18%) | 5/241 (2%) | 5/241(2%) | 0/241 (0%) | 101/241 (42%) |
Voriconazole | 40/224 (18%) | 3/224 (1%) | 1/224 (0.4%) | 2/224 (1%) | 67/224 (30%) |